Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Stomach Neoplasms × AZD4547 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Stomach Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Muscle Invasive Bladder Cancer 1 Multiple Myeloma 1 Lymphoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 FGFR1 Gene Amplification 1 Carcinoma, Squamous Cell 1 Adenocarcinoma 1

Interventions

Oxaliplatin 267 Capecitabine 187 Fluorouracil 165 Cisplatin 149 Docetaxel 124 S 1 (combination) 121 Paclitaxel 112 Leucovorin 109 Irinotecan 98 pembrolizumab 90 Trastuzumab 61 apatinib 54 Nivolumab 50 Drug Therapy 40 sintilimab 38 Radiotherapy 36 Surgical Procedures, Operative 35 Bevacizumab 34 Ramucirumab 32 Carboplatin 30 titanium silicide 27 tislelizumab 27 Hyperthermic Intraperitoneal Chemotherapy 27 Epirubicin 27 Cyclophosphamide 24 XELOX 23 Tegafur 22 camrelizumab 19 Folfox protocol 19 Cetuximab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01457846 2017-03-07

SHINE

AstraZeneca

Phase 2 Terminated

960 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡